🔎 Trials Near Me

Pradžia › Difuzinė didelė B ląstelių limfoma › Minesota

Difuzinė didelė B ląstelių limfoma klinikiniai tyrimai Minesota

16 tyrimai dėl Difuzinė didelė B ląstelių limfoma ieško dalyvių vietose Minesota.

Miestai Minesota

Oficialus tyrimo tekstas (anglų kalba)

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  • University of Minnesota Medical Center, Minneapolis
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06500273

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

  • Mayo Clinic Health System in Albert Lea, Albert Lea
  • Mayo Clinic Health Systems-Mankato, Mankato
  • Mayo Clinic in Rochester, Rochester
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06834373

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

  • Essentia Health Saint Joseph's Medical Center, Brainerd
  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • ir dar 3
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT06649812

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • Mayo Clinic Rochester, Rochester
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT05006716

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

  • Mayo Clinic Health Systems-Mankato, Mankato
  • Mayo Clinic in Rochester, Rochester
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT03418038

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  • Mayo Clinic - Rochester, Rochester
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT07226843

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • Mayo Clinic - Rochester, Rochester
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT07101328

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

  • University of Minnesota/Masonic Cancer Center, Minneapolis
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-25 · NCT06536049

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Mayo Clinic, Clinical Trials Referral Office, Rochester
Renkami dalyviai1/2 fazė
Amžius nuo 13 iki 90 · Visoms lytims · Atnaujinta 2026-08-06 · NCT06533579

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Mayo Clinic Rochester, Rochester
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-04 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • Mayo Clinic, Rochester
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-13 · NCT04792489

Auto Stem Cell Transplant for Lymphoma Patients

  • Masonic Cancer Center, University of Minnesota, Minneapolis
Renkami dalyviai2 fazė
Iki 75 metų · Visoms lytims · Atnaujinta 2025-11-04 · NCT03125642

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • Essentia Health Hibbing Clinic, Hibbing
  • ir dar 2
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-10-20 · NCT05890352

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

  • Mayo Clinic in Rochester, Rochester
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2024-09-26 · NCT06238648

Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.